{
  "id": "499e04b10b78101d",
  "title": "Opinion: STAT+: Sandoz chief scientific officer: What is truly necessary to establish biosimilarity?",
  "description": "The complexity of developing and manufacturing, coupled with market and regulatory dynamics, has put biosimilars out of reach for far too many patients, writes Sandoz CSO.",
  "content": "The complexity of developing and manufacturing, coupled with market and regulatory dynamics, has put biosimilars out of reach for far too many patients, writes Sandoz CSO.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2025/12/05/biosimilar-medicines-regulatory-reform-sandoz/?utm_campaign=rss",
  "published_at": "2025-12-05T09:30:00+00:00",
  "fetched_at": "2025-12-06T18:33:06.472112+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "regulatory",
    "manufacturing"
  ],
  "location": null,
  "raw_data": {
    "title": "Opinion: STAT+: Sandoz chief scientific officer: What is truly necessary to establish biosimilarity?",
    "description": "The complexity of developing and manufacturing, coupled with market and regulatory dynamics, has put biosimilars out of reach for far too many patients, writes Sandoz CSO.",
    "url": "https://www.statnews.com/2025/12/05/biosimilar-medicines-regulatory-reform-sandoz/?utm_campaign=rss",
    "published": "2025-12-05T09:30:00+00:00",
    "source": "STAT"
  }
}